Center of Teaching Experiment, Fourth Military Medical University, Xi'an, China.
J Virol Methods. 2013 Apr;189(1):47-52. doi: 10.1016/j.jviromet.2013.01.003. Epub 2013 Jan 16.
To develop a vaccine against hepatitis C virus (HCV), a multi-epitope peptide was synthesized from nonstructural proteins containing HLA-A2 epitopes inducing mainly responses in natural infection. The engineered vaccine candidate, VAL-44, consists of multiple epitopes from the HCV NS5A, NS4B and core proteins. Immunization with the VAL-44 peptide induced higher CTL responses than those by the smaller VL-20 peptide. VAL-44 induced antigen-specific IFN-γ-producing CD4+ T cells and CD8+ T cells. VAL-44 elicited a Th1-biased immune response with secretion of high amounts of IFN-γ and IL-2, compared with VL-20. These results suggest that VAL-44 can elicit strong cellular immune responses. The VAL-44 peptide stimulated IFN-γ production from viral-specific peripheral blood mononuclear cells (PBMCs) of patients infected with HCV. These results suggest that VAL-44 could be developed as a potential HCV multi-epitope peptide vaccine.
为了开发针对丙型肝炎病毒 (HCV) 的疫苗,我们从含有主要诱导自然感染中反应的 HLA-A2 表位的非结构蛋白中合成了一种多表位肽。该工程疫苗候选物 VAL-44 由 HCV NS5A、NS4B 和核心蛋白的多个表位组成。与较小的 VL-20 肽相比,VAL-44 肽免疫诱导了更高的 CTL 反应。VAL-44 诱导抗原特异性 IFN-γ 产生的 CD4+ T 细胞和 CD8+ T 细胞。与 VL-20 相比,VAL-44 引发了 Th1 偏向的免疫反应,分泌大量 IFN-γ 和 IL-2。这些结果表明 VAL-44 可以引发强烈的细胞免疫反应。VAL-44 肽刺激感染 HCV 的患者的病毒特异性外周血单核细胞 (PBMC) 产生 IFN-γ。这些结果表明,VAL-44 可以开发为一种潜在的 HCV 多表位肽疫苗。